Company news
Wuxi Xdc Cayman, Inc. (HKEX:2268) news
Wuxi Xdc Cayman, Inc. news releases on 6ix. Latest, Sep 21, 2026: WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion
Press releases & updates
WuXi XDC Celebrates GMP Release of Singapore Site, Ushering in a New Era of Global Expansion
September 21, 2026
WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development
September 17, 2026
WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
August 24, 2026
WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
August 18, 2026
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
April 6, 2026
WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
March 23, 2026
WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform
February 27, 2026
Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform
February 27, 2026
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
December 23, 2025
WuXi XDC Named the Winner of "Best CDMO" and "Best CRO" at 2025 World ADC Awards
November 6, 2025
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
September 25, 2025
WuXi XDC Continues to Deliver Robust Business Growth and Financial Results in 1H 2025, Strengthening Global CRDMO Leadership Position in Bioconjugates Industry
August 18, 2025
WuXi XDC Included in MSCI China All Share Index
August 8, 2025
WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity
August 3, 2025
WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
July 1, 2025
WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories
May 18, 2025
WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024
March 24, 2025
WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025
March 13, 2025
WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs
March 11, 2025
WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development
February 25, 2025
WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth
August 20, 2024
WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones
March 26, 2024